XML 67 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Collaborative Arrangements and Licensing Agreements, GSK (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 144,207   $ 159,767 $ 463,142 $ 435,478  
GSK [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Next payment to be achieved 15,000     15,000    
Revenue 0   $ 0 15,000 $ 0  
Deferred contract revenue $ 0     $ 0   $ 0
GSK [Member] | Revenue [Member] | Strategic Partner [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Concentration percentage 0.00%   0.00% 3.00% 0.00%  
GSK [Member] | Minimum [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Cumulative payments received $ 105,000     $ 105,000    
GSK [Member] | Bepirovirsen [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue   $ 15,000